HAYA Therapeutics
HAYA Therapeutics develops RNA-guided therapies and programmable therapeutics to reprogram disease-driving cell states and restore health through causal biology.
Classification
Profile
Funding
Funding details not yet available.
RNA-guided therapies that reprogram disease-driving cell states to reverse disease at its roots, restoring health through causal biology.
Pharmaceutical companies, biotech firms, and research institutions in the DACH region.
Up-front licensing fees and milestone payments from pharma partners · Royalties on future product sales (once candidates are commercialized) · Grant funding / non-dilutive awards for early-stage research (e.g., Struengmann Award)
Direct sales and partnerships with biotech/pharma firms for therapeutic development.
biopharma partnerships
R&D for developing RNA-guided therapeutics and causal biology platforms.
Proprietary RNA-guided therapeutic platform and causal biology methodology for programming lasting health.
Developing programmable therapeutics to reprogram cell states and reverse disease-driving conditions.
Sales-led relationships with enterprise biotech and pharmaceutical clients.
Competes in the RNA therapeutics space by differentiating through causal biology and cell state reprogramming rather than traditional symptom management.
Disease-driving cell states that require reversal to restore health rather than just managing symptoms.
- Diversify revenue early - pursue additional non-exclusive licensing deals with mid-size pharma to generate milestone cash before IND fili
First-mover advantage in lncRNA therapeutics can translate into high-value licensing deals if the platform proves reproducible across diseas · Capital efficiency hinges on converting scientific milestones into partnership revenue; delaying this may strain cash-runway given high R&D · Regulatory clarity will be a make-or-break factor; early engagem
- Scientific leadership - CEO Samir Ounzain discovered the cardiac lncRNA Wisper, a validated target that underpins the lead program, dem
No investors recorded yet.